Skip to main content
. 2021 May 15;13(5):3967–3986.

Figure 8.

Figure 8

MOR mAb (3A5C7) enhances cisplatin-induced apoptosis of hepatocellular carcinoma cells. (A) Cell apoptosis was evaluated by Annexin V-FITC/PI staining in HCC cells treated with 3A5C7 plus cisplatin or cisplatin alone at 48 hrs (***P < 0.001; ****P < 0.0001). (B) The levels of p-ERK, Bax, and Bcl-2 were determined by western blot in HCC cells exposed to 3A5C7 mAb plus cisplatin, control IgG plus cisplatin and cisplatin alone at 48 hrs. (C) Q-PCR was performed to evaluate changes in drug resistance genes in HepG2 and Huh7 cells exposed to cisplatin plus 3A5C7 mAb (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). (D and E) Flow cytometry assay and western blot to assess the apoptosis of HepG2 and Huh7 cells with or without MOR silencing (****P < 0.0001). (F and G) Flow cytometry assay and Western blot assay to detect the apoptosis of two cell lines with or without ERK overexpression (***P < 0.001; ****P < 0.0001). See Supplementary File Raw Blot Images (Figure 8B, 8E and 8G) for original blot images. Data were presented as the mean ± SEM. Student’s t-test and one-way ANOVA were used for statistical analysis.